Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program

V. N. Joish, M. R.M.T. Limcangco, E. P. Armstrong

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Pharmacists are increasingly taking on immunization roles in their communities as advocates, facilitators, and immunizers. Between 50% and 94% of people who receive a pharmacist's recommendation to be immunized accept that recommendation. Pneumococcal diseases impose a heavy burden on the health of adults in developed and developing countries. There are sound reasons for believing that much of this burden could be reduced by widespread use of the current pneumococcal vaccine. This month's column presents a cost-benefit analysis, using both published and hypothetical figures, to compare a traditional pneumococcal vaccination program with one that uses pharmacists as advocates for pneumococcal vaccination.

Original languageEnglish (US)
Pages (from-to)147-156
Number of pages10
Issue number2
StatePublished - 2001

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Cost-benefit analysis of a pharmacist-advocated pneumococcal vaccination program'. Together they form a unique fingerprint.

Cite this